Members of the French National Assembly's task force for the evaluation and control of the Social Security financing system (MECSS) has warned about the dire consequences of current government policy concerning the reimbursement of chronic disease patients. One MECSS member, Jean-Pierre Door (Union for a Popular Movement - UMP) said: "we're going to hit the wall" if nothing is changed.
The Social Security program provides 100% coverage of health care costs for 30 long-term conditions, including cancer and diabetes. A report in Les Echos notes that 10 million people, or 15% of the population, are included in the scheme, which accounts for nearly two thirds of all government health care expenditure. Mr Door warned that "they will number 12 million in 2012, 15 million in 2015..."
Previous attempts at reform have been abandoned following a public outcry over a proposal to limit some drugs considered to be non-essential. The only savings now going ahead are to restrict full reimbursement to therapies that are directly connected to the chronic condition and, in the case of patients who recover, to revoke their 100% coverage status. Mr Door described these moves as "cosmetic." Instead, he calls for the replacement of the 100% chronic disease cost coverage to be replaced by an annual means-tested cap on health spending per patient.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze